Literature DB >> 19551609

RET expression and neuron-like differentiation of pheochromocytoma and normal chromaffin cells.

J F Powers1, K L Picard, A S Tischler.   

Abstract

Receptor tyrosine kinase RET is normally expressed at low levels in chromaffin cells and high levels in sympathetic neurons. Paradoxically, it is overexpressed in subsets of pheochromocytomas. The overexpressed protein is usually wild-type, except in multiple endocrine neoplasia type 2. Possible explanations for overexpression include tumor origin from RET-expressing sympathoadrenal progenitors that escape developmental culling during embryogenesis, or reactivation of signaling pathways related to neuronal differentiation. Normal adult chromaffin and pheochromocytoma cells can undergo neuron-like differentiation in cell culture. In this investigation, cultured cells from two normal human adrenal medullas, two of three human pheochromocytomas, and one extra-adrenal paraganglioma showed RET induction corresponding with extensive nerve growth factor-induced outgrowth of neurite-like processes, while one pheochromocytoma showed neither processes nor RET induction. RET was similarly upregulated in parallel with process outgrowth in cultures of normal rat chromaffin cells and PC12 rat pheochromocytoma cells. In contrast, mouse pheochromocytoma cells that constitutively express high levels of wild-type RET together with other neuronal progenitor markers showed no further RET increase after cyclic AMP-induced process outgrowth. The RET-activating ligand GDNF was anti-apoptotic for mouse pheochromocytoma but not for PC12 cells. The findings suggest that overexpression of RET in pheochromocytomas could result either from a secondary event that activates signaling pathways mediating adult chromaffin cell plasticity or as a component of a persistent sympathoadrenal progenitor phenotype. Whether wild-type RET contributes to tumor development or is merely a lineage marker for cells at various stages of neuronal differentiation may vary, with other tumor characteristics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19551609     DOI: 10.1055/s-0029-1224136

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

1.  Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla.

Authors:  Stephanie M J Fliedner; Jan Breza; Richard Kvetnansky; James F Powers; Arthur S Tischler; Robert Wesley; Maria Merino; Hendrik Lehnert; Karel Pacak
Journal:  Cell Tissue Res       Date:  2010-04-30       Impact factor: 5.249

2.  Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia.

Authors:  S Verma; L Green-Golan; C VanRyzin; B Drinkard; S P Mehta; M Weise; G Eisenhofer; D P Merke
Journal:  Horm Metab Res       Date:  2010-05-05       Impact factor: 2.936

3.  Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice.

Authors:  James F Powers; Karel Pacak; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 4.  Past, present and future of human chromaffin cells: role in physiology and therapeutics.

Authors:  Alberto Pérez-Alvarez; Alicia Hernández-Vivanco; Almudena Albillos
Journal:  Cell Mol Neurobiol       Date:  2010-11-24       Impact factor: 5.046

5.  A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats.

Authors:  James F Powers; Brent Cochran; James D Baleja; Hadley D Sikes; Andrew D Pattison; Xue Zhang; Inna Lomakin; Annette Shepard-Barry; Karel Pacak; Sun Jin Moon; Troy F Langford; Kassi Taylor Stein; Richard W Tothill; Yingbin Ouyang; Arthur S Tischler
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

6.  Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.

Authors:  James F Powers; Parimal G Korgaonkar; Stephanie Fliedner; Alessio Giubellino; Karel Pacak; G Gary Sahagian; Arthur S Tischler
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.